文献速递妇科

宫颈癌根治性放疗后正电子发射断层显像部分代谢缓解患者的管理与预后

Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography.
PubMed 文献 · Gynecol Oncol · 2022-05-07

本研究基于1997至2013年前瞻性维护数据库,分析放疗后三个月FDG-PET显示部分代谢缓解(PMR)的宫颈癌患者。542例中81例(15%)出现PMR。结论认为PMR提示预后不良,尤其宫颈活检阳性及淋巴受累者;建议重复FDG-PET和/或活检以检测持续病灶并辅助咨询。

要点

  • 放疗后三个月FDG-PET示部分代谢缓解者占15%(81/542)。
  • 宫颈活检阳性者预后差,重复FDG-PET可发现宫颈外持续病灶。
  • 作者建议对PMR患者行重复FDG-PET和/或活检以检测持续病灶。

核心结论

  • 放疗后三个月FDG-PET示PMR提示预后不良,尤其宫颈活检阳性及淋巴受累者。
  • 作者建议对PMR患者行重复FDG-PET和/或活检以检测持续病灶并辅助咨询。

研究设计与样本

  • 回顾性分析1997至2013年前瞻性维护数据库中放疗后三个月FDG-PET示PMR的宫颈癌患者。
  • 采用描述性统计总结人口学、肿瘤特征、监测方法及治疗方式。
  • 采用Kaplan-Meier法估计无进展生存(PFS)和总生存(OS)。

主要发现

  • 542例中81例(15%)首次放疗后PET示PMR。
  • 30例行宫颈活检,其中14例(47%)为持续癌。
  • 9例接受治疗(3例手术、5例单纯化疗、1例化疗加放疗),但均死于疾病;手术、放化疗或未治疗者的PFS和OS相似。
  • 第二次监测FDG-PET对进展的PPV为91%、NPV为75%,并发现19%的宫颈外持续病灶患者。
  • 宫颈活检对进展的PPV为100%、NPV为62.5%。

临床怎么用

  • 作者建议对放疗后三个月FDG-PET示PMR的宫颈癌患者行重复FDG-PET和/或活检以检测持续病灶并辅助咨询。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the management and outcomes of cervical cancer patients initially treated with radiation who had partial metabolic response (PMR) on three-month post-radiation 18F-fluorodeoxyglucose positron emissions tomography (FDG-PET). METHODS: Cervical cancer patients treated with radiation between 1997 and 2013 who had PMR on initial post-therapy FDG-PET were identified from a prospectively maintained database. Descriptive statistics were used to summarize patient demographics, tumor characteristics, surveillance methods, and treatment modalities. Kaplan-Meier methods were used to estimate progression-free (PFS) and overall survival (OS) for patients who underwent cervical biopsy prior to additional therapies and for patients who were managed with chemotherapy, radiation, surgery or no intervention. RESULTS: PMR was identified in 81/542 (15%) women on initial post-radiation PET. Thirty women underwent cervical biopsy, of whom 14 (47%) had persistent cancer. Nine underwent treatment, (three surgery, five chemotherapy alone and one chemotherapy and radiation) but all died of disease; PFS and OS were similar whether women had surgery, chemoradiation therapy, or no treatment. A second surveillance FDG-PET had PPV and NPV of 91% and 75% for progression, respectively, and identified the 19% percent of patients with persistent disease outside of the cervix. Cervical biopsy had a higher PPV (100%) and lower NPV (62.5%) for progression. At the end of the study period, 46 (57%) patients were dead of disease, including all 8 patients (100%) with para-aortic or supraclavicular involvement. CONCLUSIONS: If PMR is identified on three-month FDG-PET following completion of radiation for cervical cancer, repeat FDG-PET and/or biopsy are indicated to detect persistence and assist in counseling. PMR predicts poor outcomes, particularly for those with positive cervical biopsies and lymphatic involvement.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Mckinnish TR, Greenwade MM, Wilkinson-Ryan I, et al. Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography. Gynecol Oncol. 2022. PMID: 35537885. doi:10.1016/j.ygyno.2022.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。